Tandem Diabetes Care (NASDAQ:TNDM) Price Target Increased to $40.00 by Analysts at Stifel Nicolaus

Tandem Diabetes Care (NASDAQ:TNDM) had its price objective raised by stock analysts at Stifel Nicolaus from $37.00 to $40.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the medical device company’s stock. Stifel Nicolaus’ target price suggests a potential upside of 16.75% from the stock’s current price.

A number of other equities research analysts have also issued reports on TNDM. Citigroup upped their target price on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. StockNews.com upgraded shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Tandem Diabetes Care presently has an average rating of “Hold” and an average price target of $37.27.

Tandem Diabetes Care Stock Up 8.0 %

TNDM stock traded up $2.53 during trading on Tuesday, reaching $34.26. The stock had a trading volume of 1,402,092 shares, compared to its average volume of 1,731,221. Tandem Diabetes Care has a 1-year low of $13.82 and a 1-year high of $40.74. The company has a current ratio of 3.83, a quick ratio of 3.02 and a debt-to-equity ratio of 0.91. The company has a market capitalization of $2.21 billion, a P/E ratio of -9.93 and a beta of 1.11. The firm has a fifty day moving average price of $30.09 and a 200 day moving average price of $25.00.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. The firm had revenue of $196.80 million during the quarter, compared to analyst estimates of $204.86 million. On average, equities analysts anticipate that Tandem Diabetes Care will post -1.62 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. RiverPark Advisors LLC bought a new position in shares of Tandem Diabetes Care in the fourth quarter valued at approximately $27,000. MCF Advisors LLC boosted its holdings in shares of Tandem Diabetes Care by 79.3% in the first quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock valued at $36,000 after acquiring an additional 445 shares in the last quarter. Signaturefd LLC boosted its holdings in shares of Tandem Diabetes Care by 871.8% in the fourth quarter. Signaturefd LLC now owns 1,691 shares of the medical device company’s stock valued at $50,000 after acquiring an additional 1,517 shares in the last quarter. Arcadia Investment Management Corp MI boosted its holdings in shares of Tandem Diabetes Care by 141.6% in the first quarter. Arcadia Investment Management Corp MI now owns 1,851 shares of the medical device company’s stock valued at $66,000 after acquiring an additional 1,085 shares in the last quarter. Finally, GAMMA Investing LLC bought a new position in shares of Tandem Diabetes Care in the fourth quarter valued at approximately $73,000.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.